Recent Updates — SUIC

On July 10, 2026, SUIC Worldwide Holdings Ltd. completed the acquisition of a 51% controlling interest in Vision Renu Corporation by issuing 30,000,000 shares of common stock valued at $25.5 million based on a closing price of $0.85 per share. The transaction is accounted for as an in-substance reverse recapitalization, resulting in the appointment of Chen King Te as Chairman and CEO, Kho Jean Jean as CFO, and Dongsheng Zou as director, while former executives Harriette Lo, Han Wei Wang, and Yee Wei Tan resigned. Vision Renu focuses on the research, development, and manufacturing of high-tech medical devices, including a scleral micro-ablation laser system for presbyopia and transcranial magnetic stimulation devices for depression treatment. SUIC Worldwide Holdings Ltd. operates in the life sciences and medical technology sector.

On July 10, 2026, SUIC Worldwide Holdings Ltd. completed the acquisition of a 51% stake in Vision Renu Corporation in exchange for 30,000,000 shares of SUIC common stock, representing approximately 35% of SUIC's total outstanding shares on a fully-diluted basis. The transaction resulted in a change of control; Harriette Lo, Han Wei Wang, and Yee Wei Tan resigned from their respective board and executive roles. Chen King Te was appointed as Chairman, Director, and CEO, and Shan Hua Peng was appointed as Director and CFO. Vision Renu specializes in high-tech medical devices, including a Scleral Micro-Ablation Laser System for Presbyopia and a Transcranial Magnetic Stimulation (TMS) device for depression. The company operates in the medical device industry, focusing on R&D and manufacturing of innovative healthcare and optometry technologies.